The current study tested the hypothesis that glucose utilization differs between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and investigated potential mechanisms for such a finding.
T he dramatic increase in obesity and related metabolic complications during the last decade threatens to reverse the progressive decrease in cardiovascular deaths realized over the last 50 years (1) . Although excess overall adiposity associates with cardiovascular morbidity and mortality, the distribution of body fat across different adipose tissue See page 852 (AT) compartments provides additional important information on risk (2, 3) . Indeed, whereas the amount of visceral adipose tissue (VAT) correlates highly with an adverse risk factor profile (4, 5) , the amount of subcutaneous adipose tissue (SAT) has a less ominous import in obese individuals (6) .
The potential clinical impact of biologic diversity between fat depots has triggered intense research to better understand physiologic and molecular differences based on AT location. Several studies have already demonstrated differences between VAT and SAT regarding secretion of inflammatory mediators, gene expression, and cell morphology. Yet glucose utilization between these 2 adipose compartments remains incompletely understood (7) (8) (9) (10) . A recent study shows that AT glucose uptake determined by fluorodeoxyglucose positron emission tomography (FDG-PET) may complement volumetric measurements of fat for the purpose of risk estimation (11) .
This study demonstrates higher FDG uptake in VAT compared with SAT in humans using the FDG-PET imaging technique, and investigates potential molecular mechanisms mediating this effect.
M E T H O D S
Human subjects and FDG-PET imaging. The institutional review board of Brigham and Women's Hospital approved the human studies. We retrospectively analyzed 31 obese patients and 26 lean patients who underwent whole-body PETcomputed tomography (CT) scanning for diagnosis or staging of primary lung cancer with respect to the intensity of FDG uptake in abdominal visceral and subcutaneous AT. Individuals exhibiting abnormal FDG uptake in the abdominal region suspicious for metastases, and 2 individuals with fat standard uptake values (SUVs) that were 8 and 18 standard deviations above the mean, were excluded from analysis. After fasting for 4 to 6 h, the patients received FDG (777 Ϯ 111 MBq, 21 Ϯ 3 mCi) intravenously, and whole-body images were acquired on a Discovery ST PET/CT scanner (General Electric, Milwaukee, Wisconsin), 83 Ϯ 22 min after tracer administration as described previously (12) . Briefly, a noncontrast CT scan was performed first for attenuation correction and localization. Immediately after the CT scan, the PET scan was acquired in 2-dimensional mode at 6 to 7 bed positions (4 min for each position). PET data were reconstructed using an ordered-subset expectation maximization iterative algorithm.
Hermes Gold 2.1 software (Hermes Medical Solutions, Stockholm, Sweden) was used for image analysis (Fig. 1) . We first created a "fat mask" of the original CT image set by removing pixels with densities below Ϫ110 HU or above Ϫ70 HU, a range corresponding to AT densities in human subjects (13) . We then divided the obtained CT fat mask by itself to acquire a binary CT fat mask in which pixels had the value of 1 in AT and 0 in all other tissues. We further resampled the original PET file to match the slice thickness and matrix size of the CT file, and multiplied the resampled PET image set by the binary CT fat mask. This operation left only those pixels in the PET image set that corresponded to the pixels with the value of 1 in the CT fat mask. We converted this PET image set into the original matrix size and proceeded with the analysis as follows. We drew regions of interest in visceral and subcutaneous AT in 15 to 25 consecutive slices to create a volume of interest (VOI). We recorded tracer activity (becquerels per cubic centimeter) in each pixel displaying a value above 0, and converted this number to the SUV using a standard formula accounting for pixel activity (becquerels per cubic centimeter), patient weight (kilograms), and injected dose (becquerels), decay corrected to the time of injection. We then averaged SUVs from each pixel in a VOI to obtain a single SUV for a given VOI in both SAT and VAT regions.
Experimental animals and isolation of stromal vascular cells. C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, Maine) and kept at a barrier animal facility of the Harvard Medical School. All experiments conformed to animal care protocols approved by the institutional review board. Mice were fed a high-fat diet (PicoLab Rodent Chow D12108, containing 40% kcal from fat, 1.25% cholesterol, 0% cholate; Research Diets, Inc., New Brunswick, New Jersey). At sacrifice, we 
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To isolate stromal vascular cells (SVCs), we minced the fat pads in phosphate-buffered saline (PBS) containing 2% bovine serum albumin and 250 U/ml of collagenase II (Worthington Biochemical Corporation, Lakewood, New Jersey), and incubated it at 37°C for 1 h. We passed the digested tissue through a 70-m nylon cell strainer (BD Biosciences, San Jose, California) and centrifuged the flow-through. After removing the supernatant, we lysed red blood cells with ACK lysis buffer (Gibco, Carlsbad, California) and washed and counted the remaining cells, which we then used for cell culture or RNA isolation, as described in the following text. Cytokines and chemicals. Murine cytokines were obtained from Peprotech (Rocky Hill, New Jersey) and tested by the manufacturer for the absence of lipopolysaccharide (LPS). We prepared all cytokine stock solutions in LPS-free sterile PBS and diluted the working solutions with culture medium before stimulation. Specific biological activities of cytokines were 1 ϫ 10 7 U/mg for IFN-gamma, 1 ϫ 10 7 U/mg for TNF-alpha, and 5 ϫ 10 8 U/mg for IL-1beta. We describe cytokine concentrations in sections detailing cell stimulations. We purchased 2-deoxy-D-glucose (2dG) and cytochalasin B from Sigma (St. Louis, Missouri), and 3H-2dG from PerkinElmer (Waltham, Maine). Glucose uptake assay. Cultured SVCs were incubated in KRH buffer (136 mmol/l NaCl, 4.7 mmol/l KCl, 1.25 mmol/l MgSO 4 , 1.25 mmol/l CaCl 2 , 50 mmol/l HEPES) for 30 min at 37°C to deplete endogenous glucose stores. Next, we added 3H-2dG and unlabeled 2dG to the cells (final concentration, 100 mol/l for each, and specific activity of 0.5 Ci/sample for 3H-2dG) with or without the inhibitor cytochalasin B (final concentration 10 mol/l) to determine carrier-nonspecific uptake (14) . We incubated cells for 5 min at room temperature, after which we removed the incubation buffer and washed the cells twice with 25 mmol/l ice-cold unlabeled D-glucose to stop uptake of radiolabeled glucose via saturation of transporters. We lysed cells with 1% Triton X-100 (Sigma). We used lysates for liquid scintillation counting (Beckman LS 6000IC counter) and protein measurements using BCA assay (Pierce, Rockford, Illinois). The net uptake of 3H-2dG by cells is normalized to protein content and expressed as nanomoles of glucose per milligram of protein per minute. We analyzed each sample in duplicate, and the values were averaged. The data presented on the graphs and in the tables represent mean Ϯ SEM of data obtained on cells from several experiments (n for each experiment is indicated in the respective figure legend). All graphs show GLUT-mediated glucose uptake (total uptake minus cytochalasin B-inhibited uptake). Cell culture and stimulations. After isolation, we cultured murine SVCs in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mmol L-glutamine. We plated cells on 24-well plates at a density of 250,000 cells/well and allowed them to adhere for 24 h, after which we stimulated them with a mixture of murine TNF-alpha and IL-1beta (10 ng/ml each). We then performed glucose uptake in cultured cells at baseline and at 24 and 48 h after stimulation. RNA isolation and analysis of gene expression. RNA isolation from the SVCs was performed using RNeasy mini spin columns (Qiagen, Germantown, Maryland), according to the manufacturer's instructions. We carried out RNA isolation from whole AT with RNeasy Lipid Tissue Midi Kit (Qiagen), according to the manufacturer's instructions. We assessed RNA concentration and purity using Nanodrop 1000 UV spectrophotometer (Thermo Scientific, Wilmington, Delaware). One microgram of RNA was reverse transcribed into complementary DNA (cDNA) using Superscript II reverse transcriptase (Invitrogen, Carlsbad, California) and oligo-dT primers (Invitrogen).
We performed quantitative polymerase chain reaction (qPCR) on 2 l of cDNA with the MyiQ Real-Time PCR Detection System (BioRad, Hercules, California) using the primer sequences indicated in Table 1 . We calculated relative expression ratios of genes in visceral fat compared with subcutaneous fat using the ⌬⌬Cq method with GAPDH mRNA expression as reference. Further details on RNA isolation and qPCR can be found in the Online Methods supplement to the article. Statistical analysis. We performed statistical analysis with the GraphPad Prism version 4.0 (GraphPad Software, La Jolla, California), StatView 5.0.1 (SAS Institute, Cary, North Carolina), and SAS version 9.1 (SAS Institute) software packages. Descriptive summaries included means, standard deviations, and percentages. The obese and lean cohorts were compared in terms of patient characteristics and fat SUV using the chi-square or Wilcoxon rank sum test. The within-subject analysis of VAT compared with SAT was a mixed models analysis of variance, with patient as a random effect and fixed effects of fat depot (SAT or VAT) and cohort (obese or lean). Potential confounding variables were added to the model individually, with each model having 3 fixed effects. Reliability of VAT and SAT SUV values in a subset of 8 obese and 8 lean patients was assessed by the Pearson correlation coefficient between the first and second repeated measures, the 95% confidence interval around the mean difference, and the intraclass correlation coefficient with 95% confidence interval. Statistical analysis on graphs 2 and 4 was performed using the Mann-Whitney U test, and the Wilcoxon signed rank test was used on graph 3. Nominal p values were reported, unadjusted for multiple testing.
R E S U L T S
We assessed FDG-PET scans from 31 obese (body mass index [BMI] Ͼ30 kg/m 2 ) and 26 lean (BMI Ͻ25 kg/m 2 ) subjects. 
GAPDH ϭ glyceraldehyde-3-phosphate dehydrogenase; GLUT ϭ glucose transporter; HK ϭ hexokinase. Values are n (%) or mean Ϯ SD. ACE ϭ angiotensin-converting enzyme; BMI ϭ body mass index; CAD ϭ coronary artery disease; NSAID ϭ nonsteroidal anti-inflammatory drug. 2 ) subjects (p Ͻ 0.0001) (Fig. 2) . Potentially important covariates, such as age, sex, diabetes, a history of coronary artery disease, hypertension or use of antihypertensive therapy, and smoking history, did not affect this difference in FDG signal associated with fat depots. FDG uptake in SAT and VAT in men and women overall and within both lean and obese groups is shown in Online Figure 1 . Medications (statins, diuretics, beta-adrenergic blockers, Ca 2ϩ -channel blockers, angiotensin-converting enzyme inhibitors, and aspirin, or a combination of drugs) also did not alter results.
To investigate the reliability of the measurement, the assessment of FDG uptake was repeated in 8 obese and 8 lean patients. Table 3 shows mean differences and 95% confidence intervals around the mean differences, along with correlations and intraclass correlation coefficients. The measurements were most reliable for subcutaneous fat, with a correlation of 0.88 (p Ͻ 0.0001) and an intraclass correlation coefficient of 0.87 (95% confidence interval: 0.68 to 0.95).
To probe the mechanisms contributing to higher FDG uptake in visceral than in subcutaneous AT, we conducted a series of ex vivo and in vitro experiments on cells obtained from mouse AT.
2-Deoxy-glucose uptake is higher in mouse SVCs from
visceral fat compared with subcutaneous fat. We first isolated SVCs from subcutaneous and visceral fat depots from mice with diet-induced obesity and measured glucose uptake in these cells. Baseline glucose uptake, normalized for protein content, was higher in SVCs from VAT compared with those from SAT (Fig. 3A) . Interestingly, there were no apparent differences in the rate of glucose uptake in animals of different ages (data not shown). These findings corroborated our PET data in humans. SVCs from visceral fat also tended to show higher glucose uptake at 24 and 48 h after plating (Fig.  3A) . TNF-alpha and IL-1beta, both important cytokines involved in AT inflammation, boosted glucose uptake in visceral and subcutaneous SVCs (Fig. 3B) .
Expression of glucose metabolism-related genes in mouse AT. To examine further mechanisms that might increase glucose uptake in visceral fat, we studied the expression of glucose metabolismrelated genes in mouse SVCs and unfractionated AT. We performed real-time PCR analysis for the expression of GLUT-1, -3, and -4, as well as HK-1 and 2, in SVCs isolated from SAT and VAT and in unfractionated AT from both depots. SVCs from VAT exhibited significantly higher expression of HK-1 compared with SVCs from SAT (Fig. 4A) . This difference was observed in SVCs when data . The horizontal line in the box plots represents the median value; the boxed area is the interquartile range, and the whiskers denote the 10th and 90th percentiles. *p Ͻ 0.05. CI ϭ confidence interval; FDG ϭ fluorodeoxyglucose; ICC ϭ intraclass correlation coefficient.
were pooled from both 8-week-old and 16-weekold mice (Fig. 4) or analyzed separately at each age (data not shown). Levels of mRNAs encoding GLUT-1, -3, and -4 were lower in SVCs from visceral fat compared with SVCs from subcutaneous fat, but these differences were of much lesser magnitude than that of HK-1 induction (Fig. 4A) . Real-time PCR on whole-fat samples from mice also revealed increased HK-1 expression in visceral compared with subcutaneous AT (Fig. 4B ).
D I S C U S S I O N
Physiologic differences between AT compartments in the body, particularly between subcutaneous and visceral depots, have long attracted attention. VAT burden portends higher cardiometabolic risk (4, 5) , whereas an increased amount of SAT shows the opposite association in obese individuals (6) . Biologically, the 2 adipose depots also differ in the spectrum of inflammatory mediators they secrete.
This study tested the hypothesis that noninvasive functional imaging could reveal metabolic differences between AT depots in intact humans. Most clinical studies to date have used volumetric quantification of AT depots by CT or magnetic resonance imaging. A recent preliminary report, however, suggested that volumetric measurements alone may not be sufficient and could be improved with a functional readout of the metabolic activity in a fat compartment by means of PET (11) . This report, however, did not investigate whether PET can detect differences between VAT and SAT compartments.
We show that VAT exhibits higher FDG uptake compared with SAT in humans in vivo. This difference remains significant after adjustment for potentially confounding covariates (age, sex, BMI, concomitant medications, or comorbidities including established diabetes, coronary artery disease, or hypertension) in the multivariate analysis. Thus, VAT displays higher metabolic activity than SAT, as assessed noninvasively in humans. Our results agree with earlier studies by Virtanen et al. (9, 10) , which showed higher rates of glucose uptake in VAT compared with SAT in groups of healthy and diabetic men under euglycemic hyperinsulinemic conditions. Although well designed, these studies enrolled only males with or without diabetes and did not assess basal rates of glucose uptake (9), which might limit the applicability of results to the general population. Our (15, 16) , we hypothesized that these cells may contribute to differential glucose uptake in VAT and SAT. SVCs derived from AT contain inflammatory cells such as macrophages and T cells. Indeed, VAT-derived SVCs isolated from diet-induced obese C57BL/6 mice exhibited significantly higher absolute rates of glucose uptake than those from SAT. We normalized glucose uptake values for protein concentration, which suggests increased rates of glucose uptake per cell of VAT rather than an increase due to greater cellularity in VAT. These findings indicate that not only increased cellularity, but also greater glucose uptake in each cell, contributes to the higher glucose uptake detected in vivo in human VAT compared with SAT.
Finally, to identify molecular mechanisms underlying differential glucose uptake in VAT and SAT, we assessed the expression of genes involved in the transport and phosphorylation of glucose. GLUTs mediate cellular uptake of this sugar (17) . Upon entering the cell, glucose undergoes phosphorylation by hexokinase (HK), which exists in 2 main isoforms (HK-1 and HK-2) exhibiting different tissue localization (18) . VAT-derived SVCs show higher HK-1 expression than SAT-derived SVCs. At the same time, expression of GLUT-1, -3, and -4 was lower in VAT-derived SVCs, but exhibited much smaller differences between SAT-and VATderived SVCs, which raises questions regarding their biological contribution to the differences observed in glucose uptake. Moreover, HK-1 expression was also higher in unfractionated VAT compared with SAT, whereas GLUT-1, -3, and -4 and HK-2 expression levels did not differ. This suggests that the reduced expression of GLUT-1, -3, and -4 and HK-2 in SVCs within the VAT may be compensated by their higher level of expression in non-SVCs in the same fat pad. Therefore, the increase in HK-1 expression may be sufficient to increase glucose uptake in VAT and likely results from accentuated differences in expression in the SVCs. Perrini et al. (8) likewise showed that GLUT-1 and -4 expression did not differ between VAT and SAT SVC-derived adipocytes. These observations suggest that an increase in HK-1 expression may be sufficient to increase glucose uptake in VAT, as detected noninvasively by FDG-PET. Additional studies are nevertheless necessary to draw definitive conclusions. Despite the association of obesity with inflammation, this study found no difference in FDG uptake in VAT between obese and lean individuals. We conjecture that even though SVCs in VAT from obese individuals contain more inflammatory cells, which could augment glucose uptake in VAT from obese subjects, their contribution to overall glucose uptake in such individuals may be counterbalanced by the greater mass of presumably insulin-resistant adipocytes, the most abundant cell type within this tissue. Study limitations. We quantified FDG uptake in AT using SUVs, a clinically accepted way of analyzing PET studies. Nonetheless, SUVs may have intersubject and intrasubject variability as a result of multiple factors, including plasma glucose and insulin concentrations and the time of image acquisition after FDG injection. Moreover, quantification of FDG uptake requires 4-compartment kinetic analysis (19, 20) . Such analysis was not performed in our study, and therefore, our measurements are semiquantitative in nature.
C O N C L U S I O N S
We demonstrated significant differences in metabolic activity between SAT and VAT in humans using a standard noninvasive FDG-PET technique. Investigating mechanisms underlying this observation, we found increased glucose uptake in SVCs from VAT compared with SVCs from SAT in diet-induced obese mice. Further, we showed that the increase in glucose uptake in VAT may arise, in part, to increased expression of HK-1 in VATderived SVCs. These results affirm that different fat depots associated with distinct clinical outcomes exhibit differential metabolic activity in situ in intact humans.
Visceral adiposity has become a therapeutic target for numerous novel pharmacologic and other strategies aimed at the improvement of dysmetabolism. Although plasma biomarkers provide 1 window on efficacy, availability of an imaging modality to directly probe the target tissue would help drug development programs evaluate efficacy and perform better dose selection in clinical trials. These examples illustrate potential practical applications for the use of imaging adipose tissue metabolic activity.
